MedTrace Logo

The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

NCT03368989 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2019-06-11

No results posted yet for this study

Summary

To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.

Conditions

  • Bony Metastases From Castrate Refractory Prostate Cancer

Interventions

DRUG

Radium-223 dichloride

Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Isis W Gayed, MD · The University of Texas Health Science Center, Houston

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-11
Primary Completion
2017-02-07
Completion
2017-02-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03368989 on ClinicalTrials.gov